+39 02 610346.1 - info@newron.com

Success in CNS drug development – Innovation in Rare Diseases

We are a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Our shares are listed on the SIX Swiss Exchange (NWRN).

Latest press releases

  • 5Mar
    Newron announces 2019 financial results and provides outlook for 2020

     

  • 17Feb
    Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia

     

  • 4Feb
    Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York

  • 9Jan
    Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA

     

  • 9Dec
    Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

     

  • 25Nov
    Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)

     

View All

Newron share price

Events

  • 20Apr
    H.C. Wainwright Annual Global Life Sciences Conference

    April 19-21, 2020 - London, UK

  • 21Apr
    Kempen Life Sciences Conference

    April 21-22, 2020 - Amsterdam, The Netherlands

  • 21Apr
    Swiss Biotech Day 2020

    April 21, 2020 - Basel, Switzerland

View Event Calendar